We develop, validate and implement clinical biomarker assays through our high-complexity CLIA laboratory. We have expertise across a wide range of technology platforms and sample types, with an initial focus on protein biomarkers.
We have the expertise to develop biomarker assays for remote sample collection, and implement the solution in a clinical context - from participant engagement through to data generation. Please contact us to discuss your project.
ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts.Company Overview
We help develop, validate and implement tests that enable biotech or pharma companies to obtain high-quality protein biomarker data from remote sample collection.Our Platform
Billerica MA, May 22, 2018 - ProterixBio, Inc. today announced that results from three clinical studies of subjects with chronic obstructive pulmonary disease (COPD) were presented at the American Thoracic…Read More
Billerica MA, September 12, 2017 - ProterixBio, Inc. today announced that results from a recent clinical study of subjects with chronic obstructive pulmonary disease (COPD) were presented this week at…Read More